Tumor-Associated Antigens Identification Services
- Early Cancer Diagnosis: Identifying highly specific TAAs for non-invasive serum-based diagnostic tests (e.g., HE4 for ovarian cancer, CEACAM6 for lung cancer).
- Development of Immunotherapy Targets: Providing novel and shared antigen targets for CAR-T, TCR-T, and personalized cancer vaccines.
- Tumor Mechanism Research: Investigating the role of TAAs in tumor immune evasion and metastasis, supporting drug discovery.
Tumor-associated antigens (TAAs) are proteins or peptide molecules that are abnormally or specifically expressed in tumor cells. While some TAAs exist in normal tissues, they are often significantly overexpressed in tumors or arise due to tumor-specific mutations, abnormal splicing, and other oncogenic events. TAAs serve as crucial targets for cancer immunotherapy, including CAR-T and vaccine development, as well as important biomarkers for early diagnosis and prognosis evaluation. Identifying TAAs can unveil the molecular mechanisms of tumor development, guide personalized treatment strategies, and accelerate the innovation of therapies such as immune checkpoint inhibitors and cellular therapies.
Feola, S. et al. Cancers (Basel). 2020.
Figure 1. Classification of Tumor Antigens
The identification of TAAs primarily relies on the following methods:
1. Multi-omics analysis (genomics, transcriptomics, and proteomics) integrated with bioinformatics predictions.
2. Immunoprecipitation (IP) coupled with MS to enrich HLA-bound antigenic peptides.
3. Serological screening (e.g., ELISA-based detection of autoantibodies in patient sera).
4. High-throughput sequencing (NGS) combined with mutation profiling to discover tumor-specific neoantigens.
Services at MtoZ Biolabs
MtoZ Biolabs offers a comprehensive Tumor-Associated Antigens Identification Services leveraging cutting-edge experimental platforms and multi-omics integration. We provide a full workflow solution from candidate antigen discovery to functional validation, assisting clinical institutions and research teams in efficiently identifying highly specific and immunogenic TAAs. Our Tumor-Associated Antigens Identification Services facilitates cancer diagnosis, drug target discovery, and the design of personalized immunotherapy strategies.
Analysis Workflow
1. Cell Sample Preparation and Protein Separation
Protein lysate is extracted from samples, followed by separation using IEF or SDS-PAGE.
2. Identification of Tumor-Specific Proteins
Potential tumor-associated proteins are identified by Western blotting through comparisons of protein profiles between cancer and normal samples. The proteins are then digested and analyzed by mass spectrometry (MS) for precise identification and characterization of target antigens.
3. Functional Validation of Candidate TAAs
Target antigen expression in tumor and non-tumor samples is assessed to determine its biological significance.
Li, J. et al. Front Immunol. 2021.
Figure 2. Tumor-Associated Antigens Identification Using a Proteomic Approach
Why Choose MtoZ Biolabs?
1. Multi-Omics Data Integration for Comprehensive Coverage
We integrate genomic, transcriptomic, proteomic, and immunomic data, overcoming the limitations of single-technology approaches. This enhances TAA detection rates and accuracy, ensuring a more robust identification process.
2. High-Sensitivity Platform
Our tumor-associated antigens service utilizes next-generation mass spectrometry (MS) and NGS technologies, enabling the detection of low-abundance antigens from as little as μg-level samples. It is ideal for small sample sizes and heterogeneous tumors.
3. Customized Analysis Strategies
We tailor our analytical approach based on research objectives, whether for diagnostic biomarkers, therapeutic targets, or vaccine development and we accept multiple cancer types, including solid tumors and hematologic malignancies.
4. Expert Team Support
Our team comprises experts in tumor immunology, bioinformatics, and clinical medicine, providing comprehensive support from experimental design to data interpretation.
Applications
Deliverable
1. Candidate TAA List: Detailed information on mutated neoantigens, overexpressed antigens, and HLA-presented peptides, including sequence, expression levels, and immunogenicity scores.
2. Experimental Validation Data: Raw mass spectrometry data, T-cell activity assay results, and tissue expression profiles.
3. Comprehensive Analysis Report: Functional annotation of antigens, including pathway enrichment and interaction network analysis.
The accurate identification of tumor-associated antigens is the cornerstone of successful cancer immunotherapy. MtoZ Biolabs provides a comprehensive, data-driven, and translationally focused Tumor-Associated Antigens Identification Services to support basic research, clinical diagnostics, and drug development. We are your trusted partner in unlocking tumor immunology and advancing precision oncology. Contact us today to start your high-value tumor-associated antigens discovery journey!
How to order?
